

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

PE anti-mouse CD3

RRID:AB_312662

Type: Antibody

Proper Citation

BioLegend Cat# 100205, RRID:AB_312662

Antibody Information

URL: http://antibodyregistry.org/AB_312662

Proper Citation: BioLegend Cat# 100205, RRID:AB_312662

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_312662

Vendor: BioLegend

Catalog Number: 100205

Alternative Catalog Numbers: 100206

Record Creation Time: 20250820T051328+0000

Record Last Update: 20250820T210607+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD3.

No alerts have been found for PE anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 48 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOA as a potential immunotherapy. *Cell*, 188(18), 5062.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves anti-PD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. *Cancer cell*.

Xu Y, et al. (2025) Systematic monocyte subset analysis reveals differential contribution of Notch signaling components to monocyte heterogeneity. *iScience*, 28(11), 113795.

Zeng L, et al. (2025) A subunit vaccine Ag85A-LpqH focusing on humoral immunity provides substantial protection against tuberculosis in mice. *iScience*, 28(1), 111568.

Li P, et al. (2025) ROR γ t is crucial for gut homeostasis by regulating the expression of HB-EGF rather than IL-22 in activated ILC3s. *Cell reports*, 44(6), 115793.

Zhao R, et al. (2025) Targeting AQP5-mediated arginine deprivation in gastric cancer stem cells restores NK cell anti-tumor immunity. *Cell reports. Medicine*, 6(9), 102333.

Nakayama Y, et al. (2025) Targeted labeling and depletion of alveolar macrophages using VeDTR mouse technology. *iScience*, 28(3), 111975.

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. *Cell reports. Medicine*, 6(12), 102510.

Lee W, et al. (2025) Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. *Cancer cell*, 43(1), 69.

Hong D, et al. (2025) Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer. *Developmental cell*.

Cohen SJ, et al. (2025) Liver microbial DNA signatures and extracellular vesicle epitopes as predictors of post-hepatectomy liver failure. *iScience*, 28(10), 113618.

Yin Y, et al. (2025) Activated T cells degrade extracellular proteins to enhance effector functions. *Cell reports*, 45(1), 116797.

Lad M, et al. (2024) Glioblastoma induces the recruitment and differentiation of dendritic-like "hybrid" neutrophils from skull bone marrow. *Cancer cell*, 42(9), 1549.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. *Cell reports*, 43(4), 114041.

Chen S, et al. (2024) Application of a bespoke monoclonal antibody panel to characterize immune cell populations in cave nectar bats. *Cell reports*, 43(9), 114703.

Yang Y, et al. (2024) The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. *EMBO molecular medicine*, 16(4), 885.

Ren G, et al. (2024) Decreased GATA3 levels cause changed mouse cutaneous innate lymphoid cell fate, facilitating hair follicle recycling. *Developmental cell*, 59(14), 1809.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. *Cancer cell*, 42(6), 985.

Liu G, et al. (2024) The association of appendectomy with prognosis and tumor-associated macrophages in patients with colorectal cancer. *iScience*, 27(9), 110578.

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. *Cancer cell*, 42(7), 1286.